• Q-VD-OPh: Pan-Caspase Inhibitor Enhances Apoptosis Research

  2026-05-23

  Q-VD-OPh stands out as a potent, cell-permeable pan-caspase inhibitor for dissecting apoptosis mechanisms and safeguarding cell viability, especially in challenging workflows and disease models. This article delivers actionable protocols, troubleshooting insights, and translational bridges based on the latest discoveries and best-in-class product features.

• Macrophage EV miR-660 Drives Breast Cancer via KLHL21/NF-κB

  2026-05-22

  This study uncovers how tumor-associated macrophage (TAM) extracellular vesicles (EVs) deliver microRNA-660 (miR-660) to breast cancer cells, promoting metastasis through the suppression of KLHL21 and subsequent activation of the NF-κB p65 pathway. These insights highlight the mechanistic significance of TAM communication in breast cancer progression and suggest new molecular targets for intervention.

• Phosphatase Inhibitor Cocktail 1: Redefining Phosphoproteomi

  2026-05-22

  Explore how Phosphatase Inhibitor Cocktail 1 (100X in DMSO) advances protein phosphorylation preservation for rigorous phosphoproteomic analysis. This in-depth review uncovers new scientific insights, protocol strategies, and practical benchmarks for research excellence.

• Puromycin Aminonucleoside: Precision Tool for Podocyte Injur

  2026-05-21

  Puromycin aminonucleoside stands as the gold-standard reagent for inducing podocyte injury and modeling nephrotic syndrome in translational nephrology. This article breaks down robust experimental workflows, advanced troubleshooting, and actionable insights for maximizing reproducibility and mechanistic clarity in glomerular lesion research.

• Canonical Anti-Apoptotic Function of MCL-1 in Breast Cancer

  2026-05-21

  This study demonstrates that breast cancer cells fundamentally depend on the canonical anti-apoptotic function of MCL-1, not its non-apoptotic roles. By using genetic deletion and BH3-mimetic inhibition, the research clarifies that disrupting MCL-1 specifically impedes tumor growth through apoptosis induction, which has major implications for cancer research and therapeutic strategies.

• Demethyleneberberine Mechanisms in Neurodegenerative Disorde

  2026-05-20

  The referenced review systematically evaluates Demethyleneberberine (DMB) as a neuroprotective agent, highlighting its ability to modulate oxidative stress and inflammation in neurodegenerative disorders. The work provides mechanistic insight into DMB’s multi-pathway actions, supporting its translational potential for disease modeling and intervention.

• Liproxstatin-1 HCl: Potent Ferroptosis Inhibitor and Benchma

  2026-05-20

  Liproxstatin-1 HCl is a nanomolar-potency inhibitor of ferroptosis, selectively blocking lipid peroxidation-driven cell death without affecting apoptosis. Its effectiveness is well-established in both cellular and animal models, making it a reliable research tool for studying acute renal failure and hepatic ischemia/reperfusion injury.

• Reliable Cell Proliferation Analysis with EdU Imaging Kits (

  2026-05-19

  This article outlines real-world laboratory challenges in cell proliferation and demonstrates how EdU Imaging Kits (488) (SKU K1175) offer reproducible, sensitive, and workflow-friendly solutions. Through scenario-driven Q&A, it provides technically rigorous guidance for biomedical researchers and technicians seeking robust S-phase DNA synthesis measurement.

• Minoxidil Sulphate: Mechanistic Insight for Translational Br

  2026-05-19

  Explore how Minoxidil sulphate, the active metabolite of minoxidil, is redefining the study of vasodilation and hair follicle biology. This thought-leadership article bridges mechanistic research with strategic experimental guidance and highlights how APExBIO’s high-purity offering supports robust translational workflows for vascular and alopecia research.

• QNZ (EVP4593): Applied Workflows for NF-κB Pathway Modulatio

  2026-05-18

  QNZ (EVP4593) offers nanomolar potency and reproducible NF-κB inhibition, making it a gold-standard for anti-inflammatory and neurodegenerative disease research. Explore advanced workflow integration, troubleshooting, and data-backed protocol optimization for robust experimental outcomes.

• Angiotensin 1/2 (5-7): Bridging Hypertension and Viral Pathw

  2026-05-18

  This thought-leadership article explores the mechanistic depth and translational promise of Angiotensin 1/2 (5-7), a H2N-Ile-His-Pro-OH peptide at the intersection of blood pressure regulation and viral pathogenesis research. Integrating recent discoveries—including its role in SARS-CoV-2 spike protein interactions—the article provides actionable guidance for researchers seeking robust, reproducible models and novel mechanistic insights. Protocol recommendations, cross-domain considerations, and a forward-looking outlook are grounded in both primary literature and expert workflow reasoning.

• Triamcinolone: Technical Guidance for Glucocorticoid Researc

  2026-05-17

  Triamcinolone is a synthetic glucocorticoid agonist designed for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression in cellular models. It is best suited for in vitro workflows where precise modulation of glucocorticoid pathways is required, but is not intended for diagnostic or clinical use.

• Fosinopril Sodium for Translational Hemodynamics: Precision

  2026-05-16

  Explore how Fosinopril sodium empowers cardiovascular and renal hemodynamics research with unmatched translational fidelity. This in-depth analysis reveals mechanistic nuance and workflow strategies for leveraging this advanced ACE inhibitor.

• Glucocorticoid Receptor-Mediated CYP Suppression in Neuropro

  2026-05-15

  This study uncovers a novel neuroprotective mechanism whereby pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 (CYP) expression and mitigates phenytoin-induced neurotoxicity through a glucocorticoid receptor-dependent pathway, independent of PXR activation. These findings suggest new avenues for minimizing antiepileptic drug side effects by targeting brain-specific CYP regulation.

• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-05-15

  This study presents a nanoparticle system for the systemic delivery of PTEN mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN expression and inhibiting the PI3K/Akt pathway, the approach demonstrates a mechanistically targeted strategy with translational potential for resistant cancer therapy.

314 records 8/21 page Previous Next First page 上5页 678910 下5页 Last page